Hexarelin

Hexarelin (examorelin) is a synthetic hexapeptide and one of the most potent growth hormone-releasing peptides (GHRPs) ever developed for research. Structurally, hexarelin belongs to the GHRP family of peptides — including GHRP-2, GHRP-6, and Ipamorelin — all of which activate the ghrelin receptor (growth hormone secretagogue receptor 1a, GHS-R1a) in the pituitary gland and hypothalamus to stimulate GH release. Within this chemical class, hexarelin is distinguished by its exceptional potency at the GHS-R1a, producing some of the largest acute GH pulses of any synthetic GHRP tested in humans, and by a secondary mechanism of action involving cardioprotective effects that are entirely independent of its GH-releasing activity — one of the more fascinating dual-action profiles in the peptide research space.

Hexarelin was developed in the late 1980s and 1990s as part of the systematic exploration of small peptide GH secretagogues. Its hexapeptide structure — Histidine-D-2-methyl-Tryptophan-Alanine-Tryptophan-D-Phenylalanine-Lysine — is sufficiently compact to be chemically synthesised easily and metabolically stable enough for subcutaneous administration. In human subjects, hexarelin produces a pronounced, dose-dependent acute elevation of GH that reaches its peak approximately 15–30 minutes post-injection and returns to baseline within 2–3 hours. The GH peak achieved with hexarelin (particularly in conjunction with a GHRH analog) exceeds what Ipamorelin achieves at comparable doses, reflecting hexarelin's higher intrinsic efficacy at GHS-R1a.

However, hexarelin's potency at GHS-R1a comes with a cost that Ipamorelin avoids: activation of GHS-R1a on corticotroph cells and other pituitary populations produces simultaneous elevation of ACTH and cortisol, and stimulation of lactotroph populations elevates prolactin. In human studies, hexarelin consistently elevates cortisol and prolactin significantly more than Ipamorelin does at doses that produce comparable GH release. These "dirty" side effects of hexarelin's broad GHS-R1a activity are the primary reason it is generally considered inferior to Ipamorelin for routine daily GH optimisation protocols — cortisol elevation counteracts many of the desirable effects of GH (anabolism, fat loss, recovery) and chronic prolactin elevation can suppress sex hormones over extended use. For applications where maximal acute GH stimulation is the primary goal — such as GH stimulation testing or very short-term muscle building protocols — hexarelin's potency advantage may outweigh these drawbacks.

The cardioprotective properties of hexarelin represent a genuinely distinct mechanism from its GH-axis effects and constitute perhaps the most scientifically interesting aspect of its pharmacology. Bodart and colleagues initially demonstrated in isolated heart preparations that hexarelin protected cardiac function during ischaemia-reperfusion injury — and crucially, this cardioprotective effect was fully preserved in hypophysectomised animals from which the pituitary gland had been surgically removed, eliminating GH as a mediator. Subsequent research identified CD36, a scavenger receptor expressed on cardiomyocytes, macrophages, and endothelial cells, as a key binding partner for hexarelin through which it activates cardioprotective signalling. When hexarelin binds to CD36 on myocardial cells, it activates pro-survival kinase cascades including ERK1/2 (extracellular signal-regulated kinase) and the PI3K-Akt pathway, which reduces cardiomyocyte apoptosis, limits infarct size in experimental models, and improves post-ischaemic contractile recovery. Additional research has demonstrated hexarelin's ability to reduce lipid accumulation in macrophages via CD36 modulation, potentially contributing to anti-atherosclerotic effects.

This dual mechanism — GHS-R1a-mediated GH release plus CD36-mediated cardioprotection — makes hexarelin a uniquely interesting research tool for understanding how peptide ligands can simultaneously activate multiple receptor systems with distinct signalling pathways. Whether the cardioprotective effects at doses relevant to GH stimulation research are clinically meaningful in human subjects has not been definitively established, but the preclinical data is mechanistically compelling and has generated ongoing interest in CD36-targeting peptides for cardiac applications.

A significant limitation of hexarelin that distinguishes it from Ipamorelin and CJC-1295 is its susceptibility to tachyphylaxis — rapid receptor desensitisation with repeated dosing. When administered continuously or at high frequency, GHS-R1a undergoes desensitisation and internalisation, progressively blunting the GH response over 4–8 weeks of daily use. This tachyphylaxis requires researchers using hexarelin to cycle its use, with breaks of at least equal length to the active protocol to allow receptor resensitisation. Ipamorelin, by contrast, is significantly more resistant to tachyphylaxis at standard doses — a practical advantage for sustained GH optimisation protocols.